Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SLAM DRILLS MORE COPPER MINERALIZATION AT GOODWIN (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Pharmadrug Inc C.PHRX

Alternate Symbol(s):  LMLLF

Medical Care Cannabis
PharmaDrug Inc. is a Canada-based specialty pharmaceutical company. The Company is focused on the research, development and commercialization of controlled-substances and natural medicines, such as psychedelics and previously approved drugs. The Company’s subsidiary, Sairiyo Therapeutics (Sairiyo), is a biotech company that specializes in researching and reformulating established natural medicines. Sairiyo is engaged in the development of its patented reformulation of cepharanthine, a drug that has shown substantial third party validated potential for the treatment of infectious diseases (including Covid-19) and rare cancers. In clinical research, Cepharanthine exhibits multiple pharmacological effects, including anti-oxidative, anti-inflammatory, immuno-regulatory, anti-cancer, anti-viral and anti-parasitic properties. Sairiyo is also conducting research and development (R&D) in the psychedelics space for the treatment of non-neuropsychiatric conditions.


CSE:PHRX - Post by User

Pharmadrug Inc > BUZZ made New psychedelic ETF portfolio
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(15)
•••
Comment by SamRothsteinon Jan 14, 2021 4:53pm
66 Views
Post# 32300046

RE:RE:RE:RE:RE:RE:BUZZ made New psychedelic ETF portfolio

RE:RE:RE:RE:RE:RE:BUZZ made New psychedelic ETF portfoliogood point on SPOR.  That 100 to 1 reverse split comment was really out of left field.  I thought maybe they knew something but it seemed (and still does) really unlikely to me.  At this point at least.  

JethroBlack wrote: Our MC will pop up fast. Funny how SPOR which is smaller hit 27 cents before and current 15. Right now its still above our 13 fairvalue, Mstar. Even more funny are bashers trying to say some reverse stock split is coming lol. Not a chance. MMED is being added to ETF, really took sector nice and green today, good to see. 


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities